Breaking News Instant updates and real-time market news.

LXRX

Lexicon

$18.07

0.17 (0.95%)

07:15
10/03/16
10/03
07:15
10/03/16
07:15

Lexicon presents data from TELECAST Phase 3 study at NANETS

Lexicon Pharmaceuticals announced that data from its TELECAST Phase 3 study were presented at the 2016 Annual Symposium of the North American Neuroendocrine Tumor Society, held September 30 to October 1 in Jackson, Wyoming, by Dr. Marianne Pavel in a presentation, entitled "Efficacy and Safety Results of Telotristat Ethyl in Patients with Carcinoid Syndrome During the Double-blind Treatment Period of the TELECAST Phase 3 Clinical Trial." Safety and tolerability was one of the primary objectives of the TELECAST study, and telotristat ethyl was well tolerated during the double-blind treatment period. Across all three treatment arms (placebo, 250 mg, 500 mg, each taken three times daily), the incidence of treatment-emergent adverse events were 80.8%, 100% and 84.0%, respectively; the incidence of serious AEs were 19.2%, 4.0% and 8.0%, respectively; and discontinuation due to AEs were 3.8%, 8.0% and 0%, respectively. AEs of depression or depressed mood were seen in two patients (7.7%) in the placebo arm and one (4.0%) in each of the telotristat ethyl treatment arms. Gastrointestinal AEs were seen in 57.7%, 64.0% and 36.0% of patients in the placebo, 250 mg and 500 mg treatment arms, respectively. Telotristat ethyl met the study's primary efficacy endpoint, the percent change from baseline in urinary 5-hydroxyindoleacetic acid (5-HIAA, the main metabolite of serotonin) at week 12, the final week of the double-blind treatment portion of the study (pless than0.001 for both telotristat ethyl arms compared to placebo). The placebo-adjusted change in 5-HIAA was -54.0% and -89.7% for the 250 mg and 500 mg treatment arms, respectively. In addition, despite the lower baseline bowel movement frequency than in TELESTAR, telotristat ethyl achieved statistically significant reductions in daily bowel movement frequency over the 12 weeks of the study (p=0.004 for the 250 mg treatment arm and pless than0.001 for the 500 mg treatment arm compared to placebo). Baseline mean daily bowel movement frequency was 2.2, 2.5 and 2.8 in the placebo, 250 mg and 500 mg arms. Patients in the 250 mg and 500 mg dose arms experienced noteworthy reductions in daily bowel movement frequency early in the study that tended to increase over time. The placebo-adjusted reduction in daily bowel movement frequency over the entire 12-week period was -0.45 and -0.54 for the 250 mg and 500 mg treatment arms, respectively. Notably, 40% of patients in each of the telotristat ethyl treatment arms achieved a greater than or equal to30% reduction in BM frequency for at least 50% of the days in the double-blind treatment period, while not a single patient in the placebo arm achieved that result (p=0.001 for both doses compared to placebo).

  • 30

    Nov

  • 28

    Feb

LXRX Lexicon
$18.07

0.17 (0.95%)

05/05/16
COWN
05/05/16
INITIATION
COWN
Market Perform
Lexicon coverage assumed with a Market Perform at Cowen
05/31/16
WEDB
05/31/16
NO CHANGE
Target $30
WEDB
Outperform
Lexicon price target raised to $30 from $28 at Wedbush
Wedbush analyst Liana Moussatos increased the firm's multiple on peak telotristat etiprate sales to 8x from 7x to reflect the reduced risk following the FDA's acceptance of the New Drug Application and raised the firm's price target accordingly to $30 from $28. Wedbush maintains its Outperform rating on Lexicon shares.
08/02/16
SBSH
08/02/16
INITIATION
Target $21
SBSH
Buy
Lexicon initiated with a Buy at Citi
Citi analyst Yigal Nochomovitz started Lexicon Pharmaceuticals with a Buy rating and $21 price target. The analyst expects "timely approval and launch" of the company's lead drug telotristat etiprate, an add-on to standard of care to treat severe diarrhea in carcinoid syndrome patients. He believes this should provide near-term support for the stock.
09/12/16
SBSH
09/12/16
NO CHANGE
Target $25
SBSH
Buy
Lexicon price target raised to $25 from $21 at Citi
Citi analyst Yigal Nochomovitz raised his price target for Lexicon Pharmaceuticals to $25 saying sotagliflozin showed "strong efficacy" in its first Phase 3 trial in Type 1 diabetes mellitus. The analyst believes concerns over Sotagliflozin safety should be lifted on these data. He reiterates a Buy rating on Lexicon.

TODAY'S FREE FLY STORIES

VOXX

VOXX

$7.85

0.25 (3.29%)

, TEL

TE Connectivity

$78.77

-0.04 (-0.05%)

08:05
06/26/17
06/26
08:05
06/26/17
08:05
Hot Stocks
VOXX to sell Hirschmann Car Communication to TE Connectivity »

VOXX International (VOXX)…

VOXX

VOXX

$7.85

0.25 (3.29%)

TEL

TE Connectivity

$78.77

-0.04 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOFT

Hooker Furniture

$39.40

-0.85 (-2.11%)

08:05
06/26/17
06/26
08:05
06/26/17
08:05
Conference/Events
Hooker Furniture management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

NEOT

Neothetics

$2.32

0.0501 (2.21%)

08:05
06/26/17
06/26
08:05
06/26/17
08:05
Hot Stocks
Neothetics: LIPO-202 did not demonstrate improvement in Phase 2 trial »

Neothetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GTT

GTT Communications

08:05
06/26/17
06/26
08:05
06/26/17
08:05
Hot Stocks
GTT Communications to acquire Global Capacity »

GTT Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAFD

8point3 Energy

$14.62

0.22 (1.53%)

08:04
06/26/17
06/26
08:04
06/26/17
08:04
Hot Stocks
8point3 Energy increases quarterly distribution 3% to 26.42c per share »

8point3 Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

AMAG

AMAG Pharmaceuticals

$18.35

0.15 (0.82%)

, ATRS

Antares Pharma

$3.21

0.2 (6.64%)

08:04
06/26/17
06/26
08:04
06/26/17
08:04
Hot Stocks
AMAG Pharmaceuticals reports FDA filing acceptance for Makena sNDA »

AMAG Pharmaceuticals…

AMAG

AMAG Pharmaceuticals

$18.35

0.15 (0.82%)

ATRS

Antares Pharma

$3.21

0.2 (6.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 20

    Oct

VOXX

VOXX

$7.85

0.25 (3.29%)

, TEL

TE Connectivity

$78.77

-0.04 (-0.05%)

08:04
06/26/17
06/26
08:04
06/26/17
08:04
Hot Stocks
Breaking Hot Stocks news story on VOXX, TE Connectivity »

VOXX to sell Hirschmann…

VOXX

VOXX

$7.85

0.25 (3.29%)

TEL

TE Connectivity

$78.77

-0.04 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANY

Sphere 3D

$0.17

-0.0854 (-33.31%)

08:03
06/26/17
06/26
08:03
06/26/17
08:03
Conference/Events
Sphere 3D to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

FRTA

Forterra

$7.73

0.18 (2.38%)

08:03
06/26/17
06/26
08:03
06/26/17
08:03
Hot Stocks
Forterra to sell U.S. concrete, steel pressure pipe assets to Thompson Pipe »

Forterra announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

P

Pandora

$8.28

0.48 (6.15%)

, SIRI

SiriusXM

$5.35

0.11 (2.10%)

08:03
06/26/17
06/26
08:03
06/26/17
08:03
Recommendations
Pandora, SiriusXM analyst commentary  »

Pandora added to Alpha…

P

Pandora

$8.28

0.48 (6.15%)

SIRI

SiriusXM

$5.35

0.11 (2.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

TROV

Trovagene

$1.14

-0.16 (-12.31%)

08:02
06/26/17
06/26
08:02
06/26/17
08:02
Hot Stocks
Trovagene announces expansion of key claims for NPM1 patent portfolio »

Trovagene announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBHC

National Bank

$31.55

-0.18 (-0.57%)

08:02
06/26/17
06/26
08:02
06/26/17
08:02
Conference/Events
National Bank to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 18

    Sep

CKPT

Checkpoint Therapeutics

$10.00

0.25 (2.56%)

, FBIO

Fortress Biotech

$4.87

0.05 (1.04%)

08:02
06/26/17
06/26
08:02
06/26/17
08:02
Hot Stocks
Checkpoint Therapeutics commences trading on Nasdaq Capital Market »

Checkpoint Therapeutics…

CKPT

Checkpoint Therapeutics

$10.00

0.25 (2.56%)

FBIO

Fortress Biotech

$4.87

0.05 (1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

SPA

Sparton

$18.34

0.03 (0.16%)

08:02
06/26/17
06/26
08:02
06/26/17
08:02
Hot Stocks
Sparton confirms discussions with Ultra Electronics »

Sparton Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SON

Sonoco Products

$51.02

0.08 (0.16%)

08:01
06/26/17
06/26
08:01
06/26/17
08:01
Hot Stocks
Sonoco Products to acquire Clear Lam Packaging for approx. $170M in cash »

Sonoco announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

  • 19

    Oct

LC

LendingClub

$5.67

-0.03 (-0.53%)

08:01
06/26/17
06/26
08:01
06/26/17
08:01
Hot Stocks
LendingClub executives under investigation »

Shareholder and consumer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSDV

pSivida

$1.91

0.09 (4.95%)

08:01
06/26/17
06/26
08:01
06/26/17
08:01
Conference/Events
pSivida to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 13

    Jul

  • 14

    Jul

  • 26

    Sep

LPCN

Lipocine

$4.21

-0.11 (-2.55%)

08:00
06/26/17
06/26
08:00
06/26/17
08:00
Hot Stocks
Lipocine announces submission of SPA on LPCN 1107 »

Lipocine announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

BAH

Booz Allen

$32.22

-0.67 (-2.04%)

08:00
06/26/17
06/26
08:00
06/26/17
08:00
Recommendations
Booz Allen analyst commentary  »

Booz Allen selloff an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

  • 07

    Aug

SPGI

S&P Global

$146.70

1.32 (0.91%)

08:00
06/26/17
06/26
08:00
06/26/17
08:00
Options
S&P Global call buyer realizes 15% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CUTR

Cutera

$24.50

-0.2 (-0.81%)

07:59
06/26/17
06/26
07:59
06/26/17
07:59
Initiation
Cutera initiated  »

Cutera initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 30

    Jun

  • 28

    Sep

PM

Philip Morris

$119.56

-0.15 (-0.13%)

07:59
06/26/17
06/26
07:59
06/26/17
07:59
Hot Stocks
Philip Morris to invest additional EUR500M in heated tobacco facility in Italy »

Philip Morris…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRUB

GrubHub

$47.70

1.37 (2.96%)

, AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

07:58
06/26/17
06/26
07:58
06/26/17
07:58
Downgrade
GrubHub, Amazon.com rating change  »

GrubHub downgraded to…

GRUB

GrubHub

$47.70

1.37 (2.96%)

AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

AAPL

Apple

$146.28

0.65 (0.45%)

07:57
06/26/17
06/26
07:57
06/26/17
07:57
Periodicals
Apple hires Stanford researcher for digital health, Digital Commerce 360 says »

Apple has hired Sumbul…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

NBHC

National Bank

$31.55

-0.18 (-0.57%)

07:57
06/26/17
06/26
07:57
06/26/17
07:57
Hot Stocks
National Bank acquires Peoples in $143M transaction »

National Bank and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.